Stefan Milde

Stefan Milde has a strong background in scientific research and has held various positions throughout their career. Stefan is currently working as a Senior Scientist, Cellular Phenotyping at bit.bio since May 2021. Prior to that, Stefan worked as a Research Associate at the Alzheimer's Research UK Cambridge Drug Discovery Institute from August 2017 to May 2021.

Before joining the institute, Stefan served as a Postdoctoral Associate in the Department of Biochemistry at the University of Cambridge from July 2014 to July 2017. During this time, they focused on studying the role of the microglial P2Y6 receptor in mediating inflammatory neuronal loss in mouse models of Alzheimer's and Parkinson's disease.

Stefan also has experience working at The Babraham Institute. Stefan worked as a Postdoctoral Researcher from October 2013 to June 2014, where their research focused on NMNAT2, a critical axon survival factor. Prior to that, they were a PhD student at the institute from October 2009 to September 2013, investigating the effects of NMNAT2 axonal delivery, posttranslational modifications, and turnover rate on its axon protective properties.

Overall, Stefan Milde's work experience demonstrates their expertise in cellular phenotyping, neurodegenerative diseases, and axon survival factors.

Stefan Milde completed their Bachelor of Arts (B.A.) degree in Natural Sciences at the University of Cambridge from 2006 to 2009. Stefan then pursued further education at the same institution and earned their Doctor of Philosophy (PhD) degree in Molecular Neurobiology from 2009 to 2013.